Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug ...

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Bristol Myers Squibb acknowledged that a phase III trial of luspatercept (Reblozyl) plus a Janus kinase inhibitor for ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...

Sales of Reblozyl were $240 million in the first half of the year, as booked by BMS, with Acceleron claiming a $48 million share of the total.

Sotatercept is also subject to a partnership with Bristol-Myers Squibb, Acceleron's long-term partner for FDA-approved anaemia drug Reblozyl (luspatercept) that was reportedly also involved in ...

Bristol Myers Squibb (BMY) is pushing for Reblozyl’s label expansion despite tough competition and generic pressures.

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Replimune drug rejected by FDA; Omega raises $647M biotech fund The FDA raised issues that Replimune said hadn’t come up in meetings previously. Meanwhile, Omega reloaded with fresh funding to invest ...